continued every 1-2 weeks requiring ICU admissions. Chemotherapy (CHOP-E), for his underlying lymphoma, followed by etoposide/steroids were also ineffective at controlling his cytokine storms. Considering that he had high levels of TNF-a, infliximab was started in an attempt to control dysregulated macrophages and T-cells, and was able to successfully prevent the cytokine storms. High levels of IL-6, soluble IL-2 receptor and TNF-a were all detected during cytokine storm episodes. The patient is currently getting prepared for an allogeneic stem cell transplant.
Discussion:
We report successful control of EBV-HLH related cytokine storms, guided by TNFa levels, with weekly infliximab (Fig 1) . Hypercytokinemia is believed to result from dysregulated T cells, NK cells and macrophages as a result of failure to control the EBV viremia. In this case a TNF-a inhibitor (infliximab) was used to control dysregulated macrophages, T and NK cells and block further propagation of inflammatory cytokines. Initially infliximab was initiated on a once every 2 week schedule, however, this failed to prevent cytokine storms with high TNF-a levels. However, weekly dosing of infliximab successfully prevented cytokine storms and controlled his TNF-a levels (Fig 1) . Moreover, an attempt to taper off the weekly infliximab and etoposide resulted in relapse of his symptoms and a sharp rise in ferritin levels, a marker for HLH activity (Fig 2) . This suggests that infliximab might be an effective therapy in preventing cytokine storms related to EBV-HLH and further studies are warranted.
